{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tetanus+Toxoid+Vaccine&page=4", "query": { "intervention": "Tetanus Toxoid Vaccine", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 182, "total_pages": 19, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tetanus+Toxoid+Vaccine&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tetanus+Toxoid+Vaccine&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-06T07:47:13.212Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00118274", "title": "Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Melanoma (Skin)" ], "interventions": [ { "name": "incomplete Freund's adjuvant", "type": "BIOLOGICAL" }, { "name": "melanoma helper peptide vaccine", "type": "BIOLOGICAL" }, { "name": "multi-epitope melanoma peptide vaccine", "type": "BIOLOGICAL" }, { "name": "tetanus toxoid helper peptide", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Craig L Slingluff, Jr", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 170, "start_date": "2005-03", "completion_date": "2010-02", "has_results": true, "last_update_posted_date": "2021-04-20", "last_synced_at": "2026-10-06T07:47:13.212Z", "location_count": 3, "location_summary": "Philadelphia, Pennsylvania • Houston, Texas • Charlottesville, Virginia", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" }, { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00118274" }, { "nct_id": "NCT01346293", "title": "Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Tetanus", "Diphtheria", "Pertussis", "Measles", "Polio" ], "interventions": [ { "name": "Diphtheria and Tetanus Toxoids and Acellular Pertussis + Measles, Mumps, Rubella + Varicella Virus", "type": "BIOLOGICAL" }, { "name": "Diphtheria and Tetanus Toxoids and Acellular Pertussis + Poliovirus + MMR + Varicella Virus", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Sanofi Pasteur, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "4 Years", "maximum_age": "6 Years", "sex": "ALL", "summary": "4 Years to 6 Years" }, "enrollment_count": 3372, "start_date": "2011-04", "completion_date": "2013-09", "has_results": true, "last_update_posted_date": "2015-06-03", "last_synced_at": "2026-10-06T07:47:13.212Z", "location_count": 71, "location_summary": "Birmingham, Alabama • Pinson, Alabama • Trussville, Alabama + 60 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Pinson", "state": "Alabama" }, { "city": "Trussville", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT01346293" }, { "nct_id": "NCT05294588", "title": "Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gonorrhea Male" ], "interventions": [ { "name": "Cefixime", "type": "DRUG" }, { "name": "Ceftriaxone", "type": "DRUG" }, { "name": "Ciprofloxacin", "type": "DRUG" }, { "name": "Neisseria gonorrhoeae strain FA1090", "type": "BIOLOGICAL" }, { "name": "Meningococcal Group B Vaccine", "type": "BIOLOGICAL" }, { "name": "Influenza Vaccine", "type": "BIOLOGICAL" }, { "name": "Tetanus-diptheria Vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "University of North Carolina, Chapel Hill", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "35 Years", "sex": "MALE", "summary": "18 Years to 35 Years · Male only" }, "enrollment_count": 65, "start_date": "2022-04-18", "completion_date": "2026-02-05", "has_results": false, "last_update_posted_date": "2026-03-02", "last_synced_at": "2026-10-06T07:47:13.212Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05294588" }, { "nct_id": "NCT00197236", "title": "Immunogenicity and Safety of Havrix™ Co-Administered With a Diphtheria, Tetanus and Pertussis and a Haemophilus b Vaccine in Children Aged 15 Months", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis A" ], "interventions": [ { "name": "Havrix™", "type": "BIOLOGICAL" }, { "name": "Infanrix™", "type": "BIOLOGICAL" }, { "name": "ActHIB™", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "12 Months", "maximum_age": "13 Months", "sex": "ALL", "summary": "12 Months to 13 Months" }, "enrollment_count": 468, "start_date": "2003-11-11", "completion_date": "2007-12-03", "has_results": true, "last_update_posted_date": "2018-08-20", "last_synced_at": "2026-10-06T07:47:13.212Z", "location_count": 22, "location_summary": "Phoenix, Arizona • Oakland, California • San Ramon, California + 18 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Oakland", "state": "California" }, { "city": "San Ramon", "state": "California" }, { "city": "Wilmington", "state": "Delaware" }, { "city": "Pembroke Pines", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00197236" }, { "nct_id": "NCT00722839", "title": "Vaccine Therapy in Preventing Cytomegalovirus in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Nonneoplastic Condition" ], "interventions": [ { "name": "PADRE-CMV fusion peptide vaccine", "type": "BIOLOGICAL" }, { "name": "tetanus-CMV fusion peptide vaccine", "type": "BIOLOGICAL" }, { "name": "agatolimod sodium", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 68, "start_date": "2006-12", "completion_date": "2012-04", "has_results": false, "last_update_posted_date": "2012-06-25", "last_synced_at": "2026-10-06T07:47:13.212Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00722839" }, { "nct_id": "NCT06588530", "title": "PFAS Exposure and Immune Response to Vaccination in Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Innate Inflammatory Response", "Vaccination", "Diphtheria", "Tetanus", "Environmental Exposure", "Vaccine", "Antibodies", "Adult", "Immunity", "Pollution; Exposure" ], "interventions": [ { "name": "TENIVAC", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Rutgers, The State University of New Jersey", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "89 Years", "sex": "ALL", "summary": "18 Years to 89 Years" }, "enrollment_count": 20, "start_date": "2024-11-04", "completion_date": "2025-01-08", "has_results": true, "last_update_posted_date": "2025-12-30", "last_synced_at": "2026-10-06T07:47:13.212Z", "location_count": 1, "location_summary": "Paulsboro, New Jersey", "locations": [ { "city": "Paulsboro", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT06588530" }, { "nct_id": "NCT02052596", "title": "Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) When Co-administered With GSK Biologicals' Diphtheria, Tetanus and Pertussis Vaccine (Boostrix®) in Adults Aged 50 Years and Older", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Herpes Zoster" ], "interventions": [ { "name": "Herpes Zoster vaccine GSK 1437173A", "type": "BIOLOGICAL" }, { "name": "Boostrix", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 935, "start_date": "2014-02-07", "completion_date": "2016-04-21", "has_results": true, "last_update_posted_date": "2018-04-24", "last_synced_at": "2026-10-06T07:47:13.212Z", "location_count": 13, "location_summary": "Tucson, Arizona • San Diego, California • Stockbridge, Georgia + 9 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "San Diego", "state": "California" }, { "city": "Stockbridge", "state": "Georgia" }, { "city": "Meridian", "state": "Idaho" } ], "official_url": "https://clinicaltrials.gov/study/NCT02052596" }, { "nct_id": "NCT00536120", "title": "The Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Multiple Sclerosis" ], "interventions": [ { "name": "BG00002 (natalizumab)", "type": "BIOLOGICAL" }, { "name": "keyhole limpet hemocyanin (KLH)", "type": "BIOLOGICAL" }, { "name": "tetanus diphtheria toxoid vaccine (Td)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Biogen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 60, "start_date": "2008-01", "completion_date": "2009-12", "has_results": true, "last_update_posted_date": "2017-02-15", "last_synced_at": "2026-10-06T07:47:13.212Z", "location_count": 10, "location_summary": "Fullerton, California • Centennial, Colorado • Farmington Hills, Michigan + 7 more", "locations": [ { "city": "Fullerton", "state": "California" }, { "city": "Centennial", "state": "Colorado" }, { "city": "Farmington Hills", "state": "Michigan" }, { "city": "Patchogue", "state": "New York" }, { "city": "Charlotte", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00536120" }, { "nct_id": "NCT00008853", "title": "Evaluation of Two Type III GBS Polysaccharide-Tetanus Toxoid Conjugate Vaccines", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Bacterial Infections", "Group B Streptococcus" ], "interventions": [ { "name": "GBS III-TT-SSI", "type": "BIOLOGICAL" }, { "name": "GBS III-TT-MPHL", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "FEMALE", "summary": "18 Years to 45 Years · Female only" }, "enrollment_count": 65, "start_date": null, "completion_date": "2005-11", "has_results": false, "last_update_posted_date": "2010-08-27", "last_synced_at": "2026-10-06T07:47:13.212Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00008853" }, { "nct_id": "NCT01129362", "title": "Rates of Pertussis Disease Among Persons Receiving Pentacel® or Other Pertussis Vaccines", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Pertussis" ], "interventions": [ { "name": "Pentacel® (DTaP-IPV/Hib)", "type": "BIOLOGICAL" }, { "name": "Other Pertussis Vaccines", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Sanofi Pasteur, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": null, "maximum_age": "59 Months", "sex": "ALL", "summary": "Up to 59 Months" }, "enrollment_count": 1195, "start_date": "2010-02-08", "completion_date": "2014-12-30", "has_results": false, "last_update_posted_date": "2022-04-25", "last_synced_at": "2026-10-06T07:47:13.212Z", "location_count": 2, "location_summary": "Madison, Wisconsin", "locations": [ { "city": "Madison", "state": "Wisconsin" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT01129362" } ] }